Randomised, Parallel Dose, Phase 1/2 Safety and Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps Dry Powder Inhaler in Children With Naturally Acquired Influenza A or B

Trial Profile

Randomised, Parallel Dose, Phase 1/2 Safety and Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps Dry Powder Inhaler in Children With Naturally Acquired Influenza A or B

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 24 Apr 2016

At a glance

  • Drugs Laninamivir (Primary)
  • Indications Influenza A virus infections; Influenza B virus infections
  • Focus Adverse reactions
  • Acronyms FROSTY
  • Sponsors Aviragen Therapeutics
  • Most Recent Events

    • 03 Feb 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 24 Dec 2013 New trial record
    • 23 Dec 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top